[Treatment of disorders of lipid metabolism with the new lipid regulator X50].
With the newly developed lipid regulant X 50 = 1-benzyl-3-(1-carboxyl-methylethoxy)-4-methylpyrazol 15 patient with primary hypercholesterolaemia and hypertriglyceridaemia were treated for 3 months. A significant decrease of the serum triglycerides by 47% in all patients and of the total cholesterol by 32% in half the patients (LDL cholesterol decrease 25%) was the result. Altogether an increase of the linoleic acid of 14% and a decrease of the uric acid of 16% were furthermore the result. There were practically no side effects.
D001053:Apolipoproteins / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D011720:Pyrazoles; D014280:Triglycerides; C047976:X 50
Zur Behandlung von Fettstoffwechselstörungen mit dem neuen Lipidregulans X 50.